PNPLA2 and hepatocellular carcinoma: Since we have demonstrated that ATGL overexpression redirect HCC cell metabolism towards a less glycolytic phenotype, we challenged ATGL overexpressing HepG2 cells with the glycolysis inhibitors 2-deoxyglucose (2-DG) and 3-bromopyruvate (3-BrP), at final concentrations of 30 mM and 30 μM, respectively, for 24 h.